ELVN Q1 2022 Earnings — Enliven Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ELVNEnliven Therapeutics, Inc.

$2B

Q1 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$9M

Net Income

-$9M

EPS (Diluted)

$-2.23

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$10M

Free Cash Flow

-$11M

Stock-Based Comp.

$654,000

Balance Sheet

Total Assets

$82M

Total Liabilities

$9M

Stockholders' Equity

$72M

Cash & Equivalents

$36M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	-$25,000	+100.0%
Operating Income	-$9M	-$10M	+15.6%
Net Income	-$9M	-$10M	+15.5%